Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Hanlim & Daewon ready to roll out generic Sevikar
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Oct 3, 2014 03:22:55
Hanlim and Daewon have gotten marketing approval for their generic version of Sevikar, sources said on October 1.

Sevikar contains olmesartan medoxomil and amlodipine besilate. Hanlim’s generic version contains S-amlodipine nicontinate and Daewon’s has amlodipine maleate.

Hanlim and Daewon can roll out their generic versions earlier than other competing companies. Daewon has already enjoyed the privilege of the first runner with Eswonamp, its generic version of Nexium.

The authorized generic version got approved in August. It can be rolled out before the end of the year, but the brand-name maker will consider the price reduction due to the first generic drug before rolling out the authorized generic one.

Several companies, including JW Choongwae, are trying to invalidate the patents on Sevikar. Sevikar racked up 54.2 billion won last year.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com